WO1997026337B1 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions - Google Patents

Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions

Info

Publication number
WO1997026337B1
WO1997026337B1 PCT/US1997/000895 US9700895W WO9726337B1 WO 1997026337 B1 WO1997026337 B1 WO 1997026337B1 US 9700895 W US9700895 W US 9700895W WO 9726337 B1 WO9726337 B1 WO 9726337B1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle cell
muscle
control elements
virion
selected gene
Prior art date
Application number
PCT/US1997/000895
Other languages
French (fr)
Other versions
WO1997026337A9 (en
WO1997026337A1 (en
Filing date
Publication date
Priority claimed from US08/588,355 external-priority patent/US5858351A/en
Priority claimed from US08/784,757 external-priority patent/US5962313A/en
Application filed filed Critical
Priority to JP52626797A priority Critical patent/JP2002514896A/en
Priority to EP97904823A priority patent/EP0874904A1/en
Priority to CA2243261A priority patent/CA2243261C/en
Publication of WO1997026337A1 publication Critical patent/WO1997026337A1/en
Publication of WO1997026337B1 publication Critical patent/WO1997026337B1/en
Publication of WO1997026337A9 publication Critical patent/WO1997026337A9/en

Links

Abstract

The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.

Claims

AMENDED CLAIMS[received by the International Bureau on 10 August 1997 (10.08.97); original claims 1-23 replaced by new claims 1-22 (4 pages)]
1. A method for producing a composition useful for delivering a selected gene to a smooth muscle cell or to smooth muscle tissue, said method comprising:
(a) providing a recombinant adeno-associated virus (AAV) virion which comprises an AAV vector having the selected gene operably linked to control elements capable of directing the in vivo transcription and translation thereof; and
(b) combining the recombinant AAV virion with a pharmaceutically acceptable vehicle.
2. The method of claim 1, characterized in that the selected gene encodes a therapeutic protein.
3. The method of claim 1 or 2, characterized in that the control elements comprise a muscle-specific promoter sequence.
4. The method of claim 1 or 2, characterized in that the control elements comprise an inducible promoter sequence.
5. A smooth muscle cell transduced with a recombinant AAV virion, said virion comprising an AAV vector having a selected gene operably linked to control elements capable of directing the in vivo transcription and translation of said selected gene.
6. The transduced muscle cell of claim 5, characterized in that the selected gene encodes a therapeutic protein.
- 63 -
7. The transduced muscle cell of claim 5 or 6, characterized in that the control elements comprise a muscle-specific promoter sequence.
8. The transduced muscle cell of claim 5 or
6, characterized in that the control elements comprise an inducible promoter sequence.
9. A method of transducing a mammalian smooth muscle cell, said method comprising:
(a) providing a recombinant AAV virion which comprises an AAV vector having a selected gene operably linked to control elements capable of directing the in vivo transcription and translation of said selected gene; and
(b) introducing the recombinant AAV virion into a suitable smooth muscle cell to produce a transduced muscle cell.
10. A method for producing a composition useful for delivering to a muscle cell or muscle tissue a gene encoding acid α-glucosidase, said method comprising:
(a) providing a recombinant adeno-associated virus (AAV) virion which comprises an AAV vector having said gene operably linked to control elements capable of directing the in vivo transcription and translation thereof; and
(b) combining the recombinant AAV virion with a pharmaceutically acceptable vehicle.
11. The method of claim 10, characterized in that the control elements comprise a muscle-specific promoter sequence .
- 64 -
12. The method of claim 10, characterized in that the control elements comprise an inducible promoter sequence.
13. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from skeletal muscle.
14. The method of claim 13, characterized in that the muscle cell is a skeletal myoblast or a skeletal myocyte.
15. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from smooth muscle.
16. The method of claim 10, characterized in that the composition is useful for delivering a selected gene to a muscle cell or tissue derived from cardiac muscle.
17. The method of claim 16, characterized in that the muscle cell is a cardiomyocyte.
18. A muscle cell transduced with a recombinant AAV virion, said virion comprising an AAV vector having a gene encoding acid α-glucosidase operably linked to control elements capable of directing the in vivo transcription and translation thereof.
- 65 -
19. A method of transducing a mammalian muscle cell, comprising:
(a) providing a recombinant AAV virion which comprises an AAV vector having a gene encoding acid - glucosidase operably linked to control elements capable of directing the in vivo transcription and translation thereof; and
(b) introducing the recombinant AAV virion into a suitable muscle cell to produce a transduced muscle cell.
20. The method of claim 19, characterized in that the muscle cell is derived from skeletal muscle.
21. The method of claim 19, characterized in that the muscle cell is derived from smooth muscle.
22. The method of claim 19, characterized in that the muscle cell is derived from cardiac muscle.
- 66 -
PCT/US1997/000895 1996-01-18 1997-01-17 Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions WO1997026337A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52626797A JP2002514896A (en) 1996-01-18 1997-01-17 Method for delivery of DNA to muscle cells using recombinant adeno-associated virus virions
EP97904823A EP0874904A1 (en) 1996-01-18 1997-01-17 Methods for delivering dna to muscle cells using recombinant adenoassociated virus virions
CA2243261A CA2243261C (en) 1996-01-18 1997-01-17 Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/588,355 US5858351A (en) 1996-01-18 1996-01-18 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US08/588,355 1996-01-18
US08/784,757 US5962313A (en) 1996-01-18 1997-01-16 Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US08/784,757 1997-01-16

Publications (3)

Publication Number Publication Date
WO1997026337A1 WO1997026337A1 (en) 1997-07-24
WO1997026337B1 true WO1997026337B1 (en) 1997-10-02
WO1997026337A9 WO1997026337A9 (en) 1997-10-30

Family

ID=27080262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000895 WO1997026337A1 (en) 1996-01-18 1997-01-17 Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions

Country Status (5)

Country Link
US (7) US5962313A (en)
EP (1) EP0874904A1 (en)
JP (1) JP2002514896A (en)
CA (1) CA2243261C (en)
WO (1) WO1997026337A1 (en)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
JP4002605B2 (en) * 1995-06-07 2007-11-07 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル AAV transduction of muscle tissue
US20010009904A1 (en) * 1997-12-30 2001-07-26 Jon A. Wolff Process of delivering a polynucleotide to a cell via the vascular system
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
KR20000068501A (en) * 1996-09-06 2000-11-25 트러스티스 오브 더 유니버시티 오브 펜실바니아 Method for recombinant adeno-associated virus-directed gene therapy
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
AU8672198A (en) * 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
DE69835367T2 (en) * 1997-10-29 2007-08-02 Genzyme Corp., Framingham GENE THERAPY FOR GAUCHER DISEASE
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP2002538770A (en) * 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Viral vectors and methods for their production and administration
US6303362B1 (en) * 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
WO2000031267A1 (en) * 1998-11-20 2000-06-02 The Autonomous University Of Barcelona Insulin production by engineered muscle cells
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6509150B1 (en) * 1999-03-05 2003-01-21 Universite De Nantes Compositions and methods for recombinant Adeno-Associated Virus production
JP4693244B2 (en) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helperless production of recombinant adeno-associated virus
WO2001036603A2 (en) * 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
US20040203096A1 (en) * 2001-04-09 2004-10-14 Nina Raben Synthesis and secretion of native recombinant lysosomal enzymes by liver
US7514261B2 (en) * 2001-08-09 2009-04-07 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US6838285B2 (en) 2001-09-18 2005-01-04 Becton Dickinson Site specific recombinase based method for producing adenoviral vectors
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
AU2003223775A1 (en) * 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
WO2003092598A2 (en) * 2002-04-30 2003-11-13 University Of Florida Treatment for pompe disease
CA2485341A1 (en) * 2002-05-08 2004-06-17 Intronn, Inc. Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
EP1579004B1 (en) * 2002-10-23 2010-06-16 VIRxSYS Corporation Screening methods for identification of efficient pre-trans-splicing molecules
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
ES2371913T3 (en) * 2003-01-22 2012-01-11 Duke University IMPROVED CONSTRUCTS TO EXPRESS LISOSOMAL POLYPEPTIDES.
WO2004076635A2 (en) * 2003-02-25 2004-09-10 Biovec B.V. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
US8007778B2 (en) * 2003-07-01 2011-08-30 The Regents Of The University Of California Use of calcium binding proteins to improve cardiac contractile function
CN1906162B (en) * 2003-11-12 2012-05-23 阿米库斯治疗学公司 Hydroxy piperidine derivatives to treat gaucher disease
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
WO2005070023A2 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
WO2005077333A2 (en) * 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Gel-based delivery of recombinant adeno-associated virus vectors
WO2005116224A2 (en) * 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (en) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Method for transmitting electrical, pneumatic or hydraulic energy and a power transmission system
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
WO2006083331A2 (en) * 2004-10-08 2006-08-10 Intronn, Inc Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
AU2005316476A1 (en) * 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
CN101495627A (en) * 2006-07-25 2009-07-29 塞拉东公司 Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
US20100221225A1 (en) * 2007-02-23 2010-09-02 University Of Florida Research Foundation, Inc Compositions and methods for treating glycogen storage diseases
US8221738B2 (en) * 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
DK2646044T3 (en) 2010-11-30 2019-11-25 Orphazyme As Methods to increase the intracellular activity of Hsp70
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
AU2013277215A1 (en) 2012-06-19 2015-02-05 University Of Florida Research Foundation, Inc. Compositions and methods for treating diseases
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
EP3909602A1 (en) 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
KR20240028540A (en) 2014-09-15 2024-03-05 제브라 덴마크 에이/에스 Arimoclomol formulation
RU2716991C2 (en) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Aadc polynucleotides for treating parkinson's disease
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP6863891B2 (en) 2014-11-14 2021-04-21 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Regulatory polynucleotide
EP3221456B1 (en) 2014-11-21 2021-09-22 University of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and uses thereof
CA3006569A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
MX2018012663A (en) 2016-04-16 2019-07-08 Univ Florida Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus.
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3782624A1 (en) 2016-04-29 2021-02-24 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
IL302748A (en) 2016-05-18 2023-07-01 Voyager Therapeutics Inc Modulatory polynucleotides
BR112018073472A2 (en) 2016-05-18 2019-08-27 Voyager Therapeutics Inc Huntington's disease treatment compositions and methods
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3035522A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
AU2018224044B2 (en) 2017-02-21 2024-01-25 The Uab Research Foundation Modified AAV capsid proteins and uses thereof
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
AU2018261790A1 (en) 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
CN111108198A (en) 2017-05-05 2020-05-05 沃雅戈治疗公司 Compositions and methods for treating huntington's disease
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
BR112019025888A2 (en) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polynucleotide encoding a therapeutic multi-domain protein, gene therapy vector, recombinant multi-domain therapeutic protein, expression method, methods to reduce the accumulation of glycogen in a tissue in a patient in need, to reduce the accumulation of glycogen in a tissue in a patient in need and to treat enzyme deficiency in a patient in need and / or tolerate the patient to the enzyme for which he is deficient, anti-cd63 antibody or antigen binding fragment, and pharmaceutical composition
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
JP2020534795A (en) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and Compositions for Evolving Base Editing Factors Using Phage-Supported Continuous Evolution (PACE)
JP7221275B2 (en) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Compositions and methods for delivering AAV
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
CN112639110A (en) 2018-06-22 2021-04-09 阿斯克肋匹奥生物制药公司 Vectors for gene delivery to persist in cells
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020191153A2 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
AR118465A1 (en) 2019-03-21 2021-10-06 Stridebio Inc RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
US20220204975A1 (en) 2019-04-12 2022-06-30 President And Fellows Of Harvard College System for genome editing
US20220249697A1 (en) 2019-05-20 2022-08-11 The Broad Institute, Inc. Aav delivery of nucleobase editors
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
IL292297A (en) 2019-10-17 2022-06-01 Stridebio Inc Adeno-associated viral vectors for treatment of niemann-pick disease type c
KR20230019843A (en) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
AU2021315876A1 (en) 2020-07-27 2023-02-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
IL303860A (en) 2020-12-23 2023-08-01 Univ Florida Increased packaging efficiency of vector for cardiac gene therapy
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023091949A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023196802A1 (en) 2022-04-04 2023-10-12 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
WO2023212715A1 (en) 2022-04-28 2023-11-02 The Broad Institute, Inc. Aav vectors encoding base editors and uses thereof
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024040083A1 (en) 2022-08-16 2024-02-22 The Broad Institute, Inc. Evolved cytosine deaminases and methods of editing dna using same
WO2024108092A1 (en) 2022-11-17 2024-05-23 The Broad Institute, Inc. Prime editor delivery by aav

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
AU1095595A (en) * 1993-11-10 1995-05-29 Amgen, Inc. Gene therapy vector for the treatment of low or defective red blood cell production
FR2716682B1 (en) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Process for the preparation of recombinant adeno-associated viruses (AAV) and uses thereof.
ATE386131T1 (en) 1994-04-13 2008-03-15 Univ Rockefeller AAV-MEDIATED DELIVERY OF DNA INTO CELLS OF THE NERVOUS SYSTEM
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JP4002605B2 (en) * 1995-06-07 2007-11-07 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル AAV transduction of muscle tissue
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence

Similar Documents

Publication Publication Date Title
WO1997026337B1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
CA2243261A1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
WO1997026336B1 (en) Compositions for treating anemia
Kitamura et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin
ES2237790T3 (en) USE OF GLP-1 PEPTIDES.
AU666142B2 (en) Viral recombinant vectors for expression in muscle cells
EP1927660A3 (en) Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions
Marsh et al. Cloning and structural characterization of the genes coding for adenosylcobalamin-dependent methylmalonyl-CoA mutase from Propionibacterium shermanii
CN1295617A (en) Variants of angiogenic factor vascular endothelial cell growth factor: VEGF
WO2003053363A3 (en) Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
AU704910B2 (en) Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
US9321821B2 (en) Cosmetic composition for improving skin conditions comprising fusion protein
CA2223433A1 (en) Ob protein compositions and methods
CA2067744A1 (en) The human c3b/c4b receptor (cr1)
CA2323073A1 (en) Uses for human non-autologous mesenchymal stem cells
ATE172496T1 (en) HOST-VECTOR SYSTEM FOR USE IN GENE THERAPY
CA2567177A1 (en) Genetically engineered cells for therapeutic applications
DE59915205D1 (en) Structural protein of AAV, its production and use
KR920004571A (en) Gene encoding heparin binding neurotrophic factor (HBNF), expression vectors and host cells comprising the same, and methods for producing and using HBNF
CA2326401A1 (en) Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
WO2000052136A3 (en) Human glycosylation enzymes
MacColl et al. Optimisation of growth hormone production by muscle cells using plasmid DNA
DE19850718C1 (en) Cell permeability-mediating polypeptide
EP0423641A2 (en) Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or TGFalpha